The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
SALT LAKE CITY , July 1, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...
Buying stocks that can make you millions is any investor's dream. That is why some investors consider micro-cap or small-cap stocks trading under $10....
SALT LAKE CITY , May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...
Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & Chief Executive Offic...
SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
SALT LAKE CITY , April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bio...
Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
Sera Prognostics specializes in women's health diagnostics with its PreTRM test, offering personalized risk assessment for preterm birth. The PreTRM test analyzes specific proteins and gestational age...
Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript...